Ironwood Pharmaceuticals issues 2026 financial guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. SPCX
2. SBUX
3. LEVI
4. NVDA
5. GOOGL
6. ORCL
7. USO
8. STZ
9. AAPL
10. SPY

Go back to Ironwood Pharmaceuticals issues 2026 financial guidance

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

January 2, 2026 7:05 AM EST

- Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million -

- Ended Q4 2025 with greater than $200 million in cash and cash equivalents -

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company... More